Debiopharm products

Multilink™ is a new cleavable linker platform suited for multidrug attachment and compatible with any conjugation technology to produce ADCs with high DAR (drug-to-antibody ratio).

Oxaliplatin is a diaminocyclohexane (DACH) platin. It is the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®, which has dramatically changed the prognosis of colorectal cancer. In 1996, prior to the introduction of oxaliplatin, the standard of care for colorectal cancer was 5-fluorouracil (5-FU). Combination of oxaliplatin with 5-FU and leucovorin (FOLFOX) allowed to more than double the survival of patients with metastatic disease. In 2000’s approval of oxaliplatin in adjuvant settings has significantly increased the number of patients cured. It is a worldwide standard treatment in metastatic colorectal cancer.

AbYlink™ is an antibody conjugation technology ideally suited for therapeutic and diagnostic applications. Thanks to AbYlink™, cytotoxic or imaging cargos can be selectively attached to the Fc portion of any IgG without prior modification of the antibody. This technology preserves the original affinity of the antibody to its target.

Triptorelin is a gonadotropin releasing hormone (GnRH) agonist; Triptorelin, the active substance of Decapeptyl/Trelstar/Pamorelin/Triptodur, is a GnRH agonist analogue. An agonist is a chemical that binds to a receptor of a cell and triggers a response by that cell. Triptorelin decreases the serum testosterone to castrate levels (estradiol in females). Androgen deprivation stops the growth of the androgen dependent prostate cancer, alleviating pain and improving thus the quality of life of patients. GnRH agonist treatment achieves similar overall survival rates in advanced prostate cancer as surgical castration.The triptorelin 1-month, 3-month and 6-month sustained release formulations have provided patients with a convenient treatment modality.